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 What ’ s known on the subject? and What does the study add? 
 Metastatic or locally advanced squamous cell carcinoma of the penis (SCCP) is 
generally incurable, but it can be palliated with systemic chemotherapy. Two 
retrospective studies, involving  < 10 patients each, showed that cisplatin plus 
continuous infusion of 5-fl uorouracil (5-FU) may be effective and well tolerated. 
Cisplatin, methotrexate and bleomycin, cisplatin and irinotecan and taxanes can also 
play an important role for patients with locally advanced/metastatic SCCP. Finally, 
anti-EGFR therapy may also be effective in advanced SCCP. 
 Although cisplatin plus continuous infusion of 5-FU is widely used in clinical practice 
for palliation of SCCP, toxicity and effi cacy data regarding this schedule include a total 
of 14 patients with SCCP, treated more than two decades ago. In our retrospective 
study, cisplatin plus continuous infusion of 5-FU was used for palliative purposes in a 
homogenous sample of 25 patients with SCCP. Partial responses and stable disease 
were observed in 8 (32%) and 10 (40%) patients, respectively, with a median 
progression-free survival of 20 weeks. Neutropenia was the most important grade 3 – 4 
side effect observed, occurring in 20% of patients. These data provide confi rmation 
that such a combination regimen is moderately effective and well tolerated in patients 
with SCCP. 
 OBJECTIVE 
 •  To investigate the activity and toxicity of 
5-fl uorouracil (5-FU) as a fi rst-line 
treatment in metastatic squamous cell 
carcinoma of the penis (SCCP). 
 METHODS 
 •  The medical records of 78 patients with 
SCCP treated between January 2000 and 
June 2011 at the four participating centres 
were reviewed. 
 •  Data regarding patients treated with 
fi rst-line 5-FU were extracted. 
 •  Patients were included in the study if 
radiological reports were available for 
determination of response and 
progression-free survival (PFS) according to 
response evaluation criteria in solid 
tumours (RECIST) 1.1. 
 RESULTS 
 •  Between January 2000 and June 2011, 
25 patients were treated with i.v. cisplatin 
on day 1 followed by 5-FU as a continuous 
24-h infusion for 4 days every 3 weeks 
until disease progression or unacceptable 
toxicity. Partial responses and stable disease 
were observed in eight (32%) and 10 (40%) 
patients, respectively, with a disease control 
rate of 72%. 
 •  Severe neutropenia was the most 
important grade 3 – 4 side effect observed, 
occurring in 20% of patients. 
 •  The median (interquartile range  [ IQR ] ) 
PFS was 20 (11 – 20) weeks and the median 
(IQR) overall survival (OS) was 8 (7 – 12) 
months. 
 CONCLUSION 
 •  5-FU is associated with a moderate 
response rate and is well tolerated in 
patients with metastatic SCCP. 
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 INTRODUCTION 
 Squamous cell carcinoma of the penis 
(SCCP), the predominant histological type 
( > 95%) of penile cancer, is rare in the 
general population. It has a heterogeneous 
incidence worldwide, which ranges from 
 < 1.00 per 100  000 males in Europe and the 
USA to 0.7 – 3 and 8.3 per 100  000 men in 
India and Brazil, respectively  [ 1 ] . Although 
survival is infl uenced by a number of 
factors, including grade, growth pattern, 
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presence of vascular embolization, tumour 
thickness, as well as degree of infi ltration of 
the surrounding tissues  [ 2 ] , the most 
prominent variable of established prognostic 
value is pathological lymph node 
involvement. In the series published by 
Bezerra  et  al.  [ 3 ] , the 5-year cancer-specifi c 
survival was between 90% and 100% in 
patients with pN0 disease, between 70% 
and 80% in those with pN1 stage and  < 30% 
in those with stage pN2-3 disease. Surgery 
and radiotherapy are the mainstay of 
treatment for patients with localized disease 
and can also be used in combination with 
adjuvant/neoadjuvant chemotherapy in 
patients with lymph node involvement, 
while chemotherapy is the main therapeutic 
option for patients with distant metastasis 
 [ 1 ] . The proportion of patients with stage IV 
disease is relatively low, ranging from 0 to 
14%, but their prognosis is dismal, with 
the majority of them dying within 1 year 
of diagnosis  [ 4 ] . A wide variety of 
chemotherapy regimens provided 
radiological responses in either retrospective 
or prospective studies in this setting, but no 
phase III trial has ever been conducted, so 
the benefi t of chemotherapy in terms of 
symptomatic palliation and survival 
prolongation remains uncertain. Cisplatin, 
used either alone  [ 5 ] or in non-bleomycin-
containing regimens such as cisplatin-5-
fl uorouracil (5-FU)  [ 6,7 ] , cisplatin-
gemcitabine  [ 8 ] , and cisplatin-irinotecan  [ 9 ] , 
is the cornerstone of chemotherapy for 
inoperable disease, with a more favourable 
toxicity profi le with respect to bleomycin-
methotrexate-cisplatin  [ 4 ] . Among cisplatin-
based regimens, a combination of cisplatin 
plus continuous infusion of 5-FU appears 
especially promising for its safety and 
effi cacy profi le, but it has been surprisingly 
poorly investigated, with a total of only 13 
patients with SCCP reported to have 
received such a regimen in retrospective 
studies in the neoadjuvant/metastatic 
setting  [ 6,7 ] . With the aim of expanding our 
knowledge of the safety and effi cacy of this 
versatile regimen in patients with advanced 
SCCP, we conducted a retrospective review 
of patients treated with this combination at 
our institutions in the period 2000 – 2011. 
Inclusion criteria were defi ned to select a 
homogeneous subset of patients with stage 
IV SCCP, who were not amenable to radical 
surgery or a neoadjuvant approach at the 
time they had been treated with cisplatin 
plus 5-FU, to allow generalization of the 
results obtained, as we have discussed 
elsewhere for retrospective studies in kidney 
cancer  [ 10 ] . 
 PATIENTS AND METHODS 
 INCLUSION CRITERIA 
 Medical records of patients with SCCP 
treated with fi rst line i.v. cisplatin plus 
continuous infusion of 5-FU between 1 
January 2000 and 30 June 2011 were 
reviewed at four participating centres. 
Patients were included in this retrospective 
analysis if they met the following criteria: (i) 
histological diagnosis of SCCP; (ii) newly 
diagnosed or recurrent disease judged not 
amenable to either radical surgery or 
neoadjuvant chemotherapy, followed by 
surgery with radical intent; (iii) availability 
of either radiological images or radiological 
reports of CT scans with contrast of the 
thorax and abdomen performed at baseline 
and at least every 4 months during 
chemotherapy, with suffi cient data to allow 
re-evaluation of response by the 
investigators according to the response 
evaluation criteria in solid tumours (RECIST) 
1.1  [ 11 ] ; and (iv) fi rst-line chemotherapy 
with i.v. cisplatin plus continuous i.v. 
infusion of 5-FU. 
 RETRIEVED DATA 
 Demographic data of eligible patients were 
retrieved, along with clinical and histological 
characteristics such as Eastern Cooperative 
Oncology Group (ECOG) performance status, 
type of surgical operation before receiving 
cisplatin + 5-FU, histological grade, stage 
at diagnosis, time from diagnosis to 
administration of cisplatin + 5-FU, dose and 
schedule used, date of initiation of 
treatment, date of progression, metastatic 
sites, date of death. Best response and 
progression-free survival (PFS) of 
cisplatin + 5-FU treatment were assessed 
by central review using radiological reports 
or radiological images according to the 
RECIST 1.1 criteria. Adverse events occurring 
within 30 days of the last chemotherapy 
cycle, defi ned according to the National 
Cancer Institute Common Toxicity Criteria 
(version 3.0), if applicable, were also 
extracted from reviewed charts. Stage was 
determined according to the TNM 
classifi cation 7 th edition  [ 12 ] . If available, 
mean pain score data, referring to the pain 
experienced by the patient and measured 
using a rating scale of 0 to 10 or 100 (0 
being no pain and 10 or 100 representing 
the most intense pain ever experienced) 
were also retrieved, along with data 
regarding analgesic use. 
 DATA ANALYSIS 
 Descriptive statistics and frequency counts 
were used to summarize characteristics of 
the study population. Median numbers are 
presented with interquartile ranges (IQRs). 
The overall response rate to cisplatin + 5-FU 
was defi ned as the percentage of patients 
who had either a complete response or a 
partial response as best response at any 
time during treatment. PFS and overall 
survival (OS) were calculated using the 
Kaplan – Meier method. PFS was calculated 
from the start of treatment to the time of 
death or radiographic progression, as 
re-determined by the investigators. Patients 
were excluded from the PFS analysis if 
progressive disease, diagnosed by the 
treating clinician, leading to chemotherapy 
interruption was not confi rmed by the 
investigators. Patients lost to follow-up, or 
who were still under treatment as of 1 
March 2012, were censored in the analysis. 
OS was calculated from the start of 
treatment to the time of death. Patients 
alive as of 1 March 2012, or who were lost 
to follow-up, were censored from the 
analysis. Univariate analysis, performed 
using Fisher ’ s exact test and the log-rank 
test, was conducted to seek a relationship 
between PFS, OS and response to 
cisplatin + 5-FU and variables of interest that 
included age, performance status, metastatic 
sites, dose intensity, grade and time from 
diagnosis to recurrence. A  P value  < 0.05 
was considered to indicate statistical 
signifi cance. Multivariate analysis was not 
deemed feasible because the expected 
sample size was not suffi ciently large. As 
described by Buonerba  et  al.  [ 13 ] ,  ‘ pain 
response ’ was defi ned as a  > 50% reduction 
in analgesic consumption, coupled with a 
 > 50% decrease in pain at any time since 
baseline after at least 1 cycle of treatment. 
Pain score, measured on a scale from 1 to 
10, was multiplied by 10 to allow median 
calculation. Pain medications were classifi ed 
as non-opioids (anti-infl ammatories, 
paracetamol, etc.) and opioids. Opioid 
intake was converted into oral morphine 
equivalents before analysis. 
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 RESULTS 
 STUDY POPULATION AND TREATMENT 
SCHEDULE 
 Of the 78 medical records evaluated for this 
retrospective review, 25 patients were fi nally 
included in the study. All patients presented 
with inoperable stage IV SCCP at the time 
they received cisplatin + 5-FU. All of them 
presented with adequate baseline renal, 
hepatic and bone marrow function (at least 
1500 neutrophils and 100  000 platelets per 
 μ Lwith minimum haemoglobin 90  g/L; 
creatinine clearance calculated by the 
cockcroft-gault equation  > 60  mg/mL/min; 
total bilirubin  < 1.5 × upper limit of normal; 
aspartate aminotransferase (AST) and 
alanine amino transferase (ALT)  < 3 × upper 
limit of normal). Cisplatin was delivered at a 
median (IQR) dose of 75  mg/m 2 (70 – 80) on 
day 1, while 5-FU was delivered via 
continuous infusion at the median (IQR) 
dose of 900 (800 – 1000) mg/m 2 for 4 days 
after cisplatin infusion in all patients every 
21 days (one cycle). Patients were generally 
seen by physicians every 3 – 4 weeks and 
radiological evaluation was performed every 
3 – 4 cycles. Information regarding pain levels 
was available for 12 patients, while data on 
analgesic consumption were available for all 
patients. All patients received some kind of 
analgesic medication, and 16 of them were 
taking opioids at the time of initiation of 
chemotherapy. Patient characteristics are 
shown in  Table  1 . 
 EFFICACY OF CISPLATIN PLUS CONTINUOUS 
INFUSION OF 5-FU 
 All included patients were evaluable for both 
response and PFS. Eight patients (32%; 95% 
CI 13.7 – 50.3) had a confi rmed radiological 
response according to the RECIST criteria. 
Stable disease was observed in 10 (40%) 
patients, while the remaining patients (28%) 
had progressive disease ( Table  2 ). No data 
regarding quality of life were available. Of 
12 patients assessable for response to pain, 
all presented a baseline pain score  ≥ 30 on a 
scale from 0 to 100 and required opioids for 
pain control. Four of them showed a pain 
response after 3, 4, 4 and 7 weeks, 
respectively. All four of them also showed 
radiological response. All patients presented 
a baseline whole body CT scan with contrast 
and were evaluated every 3 cycles, except 
for three who were evaluated every 4 cycles. 
A median (IQR) of 6 (4 – 6) cycles were 
administered, with a median relative 
delivered dose intensity of cisplatin of 
81.8%. Median (IQR) PFS was 20 (11 – 20) 
weeks, while median (IQR) OS was 8 (7 – 12) 
months ( Figs  1,2 ). 
 TOXICITIES OF CISPLATIN PLUS CONTINUOUS 
INFUSION OF 5-FU 
 Treatment was well tolerated overall. The 
most common grade 3 – 4 toxic effects were 
 TABLE  1  Patient characteristics 
No. of patients 25
Median age (range), years 63 (57 – 65)
ECOG performance status,  n 
  0 7
  1 11
  2 7
Previous loco-regional therapy,  n 
  Total amputation 10
  Partial amputation 13
  Radiotherapy 5
  Radical inguinal lymphadenectomy 16
  Radical lymphadenectomy for recurrent disease 2
Pathological T stage at diagnosis,  n 
  T1 4
  T2 15
  T3 5
Pathological N stage at diagnosis,  n 
  N0 11
  N1 4
  N2/N3 1
  Not available 9
Time from fi rst diagnosis to treatment start,  n 
  ≤ 6 months 11
  > 6 months 10
  Not available 4
Metastatic site at the time of treatment,  n 
  Lymph node only 15
  Bone 2
  Lung 5
  Liver 3
Median oral mg morphine equivalents in 16 patients on opioids (range) 60 (30 – 80)
Median baseline pain score in 12 assessable patients on a scale from 1 to 100 (range) 45 (40 – 60)
 FIG.  1.  OS of the study population. 
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 TABLE  2  Responses and survival rates 
according to the follow-up 
Response,  n (%)
  Complete response 0
  Partial response 8 (32)
  Stable disease 10 (40)
  Progression 7 (28)
Median (IQR) number of cycles 6 (4 – 6)
Median (IQR) PFS, weeks 20 (11 – 20)
Median (IQR) OS, months 8 (7 – 12)
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neutropenia, occurring in 5 (20%) patients, 
and anaemia, occurring in 3 (12%) patients. 
There was no death or interruption of 
treatment for toxicity. Dose reductions 
were necessary in seven patients (28%, 
two, two and three patients after 3, 4 and 
5 cycles, respectively). Among grade 1 – 2 
side effects, neutropenia, oral mucositis 
and nausea/vomiting were the most 
frequent, occurring in 11 (44%), 8 (32%) 
and 8 (32%) of patients, respectively 
( Table  3 ). 
 PROGNOSTIC FACTORS 
 At univariate analysis, a younger age and a 
longer time to recurrence were signifi cantly 
associated with an improved response, 
longer PFS and OS. Conversely, a lower 
histological grade and better performance 
status were signifi cantly associated with 
longer PFS and OS ( Table  4 ). 
 DISCUSSION 
 Although cisplatin can be considered the 
mainstay of fi rst-line treatment for patients 
with advanced penile cancer, it is presently 
uncertain whether its use is associated with 
a survival advantage or symptomatic 
improvement, given the lack of phase III 
trials in this setting. In an effort to increase 
the activity of single-agent cisplatin, which 
yielded a response rate of only 15.4% and 
an OS of 4.3 months in a sample of 26 
patients, a number of cisplatin-based 
combination regimens have been 
experimented in SCCP  [ 4 ] . In a phase II trial 
by Theodore  et  al.  [ 9 ] , men with locally 
advanced (25%) or men (75%) with 
metastatic SCCP received combination 
cisplatin and irinotecan, with a response 
rate of 30.8% (80% CI 18.8 – 45.1) in 26 
assessable patients. While survival was not 
reported, three patients treated in the 
neoadjuvant setting, who underwent a 
lymphadenectomy after chemotherapy, 
demonstrated no pathological evidence of 
malignancy. Additionally, a favourable 
toxicity profi le was seen. A similar response 
rate of 32.5% with a median OS of 28 weeks 
was obtained in the largest phase II trial 
conducted in patients with penile cancer, 
with 40 assessable patients treated with the 
combination of cisplatin-methotrexate-
bleomycin  [ 14 ] . Although this regimen was 
considered active according to the study 
design, toxicity was unacceptable, with fi ve 
treatment-related deaths and six of the 36 
remaining patients experiencing one or more 
life-threatening side effects. Recently, a 
phase II trial has shown a response rate of 
50% (95% CI 31 – 69%) with the combination 
of cisplatin, ifosfamide and paclitaxel in 30 
patients treated in the neoadjuvant setting, 
which was accompanied by a favourable 
safety profi le  [ 15 ] . However, only nine 
patients (30.0%) were free of recurrence 
after a median follow-up of 34 months. 
No data are available for the cisplatin-
ifosfamide-paclitaxel regimen in the 
metastatic or unresectable setting, where 
the therapeutic index may not be as 
favourable as in the neoadjuvant setting. 
Notably, as far as the use of paclitaxel in 
SCCP is concerned, we have shown that this 
drug administered as single agent at 
175  mg/m 2 every 3 weeks exhibited modest 
activity in the second-line setting, with a 
response rate of 20% (fi ve of 25 patients), 
and a median survival of 23 weeks  [ 16 ] . 
Paclitaxel has also been used in the 
neoadjuvant setting with excellent 
preliminary results in a small experience 
involving six patients with recurrent or 
inoperable nodal disease treated with a 
combination of cisplatin 5-FU paclitaxel, 
with three of them achieving a complete or 
near-complete pathological response and 
Toxicity
Grade 1 – 2, 
 n (%)
Grade 3,
 n (%)
Grade 4, 
 n (%)
Neutropenia 11 (44) 4 (16) 1 (4)
Anaemia 6 (24) 2 (8) 1 (4)
Thrombocytopenia 5 (20) 1 (4) 1 (4)
Oral mucositis 8 (32) 1 (4) 0
Nausea/vomiting 8 (32) 1 (4) 0
Peripheral neuropathy 6 (24) 1 (4) 0
Constipation 6 (24) 1 (4) 0
Alopecia 5 (20) 1 (4) 0
Hypercreatininaemia 5 (20) 0 0
Diarrhoea 1 (4) 1 (4) 0
 TABLE  3  
Toxicity data from the 25 
patients 
 TABLE  4  Univariable analysis of response rate, PFS and OS 
Variable Response rate PFS, weeks OS, months
Age 75% vs 0% 22.5 vs 20 10.5 vs 8
  < 63 vs  ≥ 63 years  P  < 0.001  P  = 0.009  P  = 0.022
T at diagnosis 35% vs 20% 20 vs 20 8 vs 8
  T1 – T2 vs T3  P  = 1  P  = 0.32  P  = 0.49
Grade 33.3% vs 28.5% 20 vs 11 8 vs 6
  G1 – 2 vs G3 – 4  P  = 1  P  = 0.025  P  = 0.001
Lymphnode involvement only vs visceral disease 33% vs 30% 20 vs 20 8 vs- 8
 P  = 1  P  = 0.298  P  = 0.486
Recurrence 0% vs 80% 20 vs 25 8 vs 12
  ≤ 6 months vs  > 6 months  P  = 0.001  P  = 0.004  P  = 0.005
ECOG performance score 44% vs 0% 20 vs 11 9 vs 5
  0 – 1 vs 2  P  = 0.057  P  = 0.002  P  < 0.001
 FIG.  2.  PFS of the study population. 
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two of them achieving a complete clinical 
remission  [ 17 ] . 
 The rationale for the use of cisplatin and 
5-FU in patients with cancer is strong, and 
includes synergy of cisplatin and 5-FU in 
animal models, different mechanisms of 
action and different dose-limiting toxicities 
of the two drugs  [ 7 ] . No prospective trial 
has been conducted with this regimen in 
patients with penile cancer. In one 
retrospective study, all of the fi ve patients 
with SCCP treated with cisplatin + 5FU 
showed partial radiological response, with 
one of these patients receiving radical 
surgery after chemotherapy. The primary 
toxicities (nausea/vomiting, renal injury, 
mucositis) were manageable and transient 
 [ 6 ] . Another retrospective study conducted 
in eight patients with advanced SCCP 
reported radiological responses in two 
patients, with three patients showing  ‘ poor 
tolerance ’ to treatment  [ 7 ] . The present 
retrospective study, to the best of our 
knowledge, represents the largest report 
of patients with penile cancer receiving 
this regimen. In the present study, we 
were able to include 25 men with 
homogeneous characteristics, all of them 
receiving fi rst-line treatment for palliative 
purposes in the setting of inoperable 
disease. As evaluation of response was 
critical for our aims, we reviewed and 
re-assessed response to treatment on the 
basis of either radiological reports or 
radiological images. The response rate 
of 32% (CI 95% 13.7 – 50.3) was in line 
with that of bleomycin-cisplatin-
methotrexate, with no toxic deaths and 
no patient interrupting treatment because 
of toxicity. 
 In the present study, we also reported an 
association of simply assessable clinical and 
pathological variables, such as age, 
performance status, time to recurrence and 
histological grade with both PFS and OS. 
Most of the available data regarding 
prognostic factors in patients with penile 
cancer concern surgical series, which 
identifi ed tumour stage and grade as 
suffi cient alone to predict survival after 
surgery  [ 18 ] . Although multivariate analysis 
was not performed in the present study, 
owing to the limited sample size, the 
variables that we identifi ed (age, grade, time 
to recurrence and performance status) may 
be helpful for stratifi cation purposes in 
clinical trials and also in clinical practice, 
provided confi rmation from larger trials is 
obtained. 
 Recently, cetuximab  [ 19 ] and panitumumab 
 [ 20 ] have been shown to provide responses 
in SCCP, employed in combination with 
docetaxel and as a single agent, respectively. 
In this regard, we believe that the positive 
results obtained in this retrospective 
study, coupled with the high expression 
of EGFR on immunohistochemistry  [ 21 ] , 
and the proved synergism of cisplatin, 
5-FU and cetuximab in head and neck 
squamous cell carcinomas  [ 22 ] , should 
prompt the investigation of such a regimen 
in SCCP. 
 In conclusion, the present retrospective 
study is currently the largest study providing 
evidence that a combination schedule, 
widely used in oncological practice, is active 
and safe in patients with inoperable SCCP. 
By contrast to the limitations of previous 
reports  [ 6,7 ] , the present study included a 
suffi ciently large, homogeneous sample of 
patients treated with similar doses and 
schedules of cisplatin plus continuous 
infusion of 5-FU. Although data presented 
here are still affected by the typical biases 
of retrospective studies, such as lack of 
study protocol, study design and data 
incompleteness, our effort to re-evaluate 
response according to the RECIST criteria 
strengthened the quality of our results, 
suggesting that this combination regimen is 
a valid fi rst-line therapeutic option in the 
metastatic setting. Prospective trials are 
required to confi rm the effi cacy and 
tolerance of this combination, and also to 
explore the additional therapeutic 
advantages of its combination with 
biological agents (e.g. cetuximab, HPV 
vaccination) or chemotherapy (e.g. taxanes). 
The neoadjuvant paradigm may enable the 
early identifi cation of signals of activity, i.e. 
pathological remission. Given poor long-
term outcomes despite initial 
chemosensitivity, the switch maintenance 
paradigm may also be worthy of 
consideration. Additionally, the discovery of 
biomarkers predictive of activity is important 
 [ 2 ] . Finally, prevention remains critically 
important. 
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